What is HC Wainwright's Forecast for IOVA FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Iovance Biotherapeutics to a loss of $0.40 per share from a projected loss of $0.49. It also forecasts losses of $0.05 per share in Q4 2026 and $0.13 in FY2027.
• HC Wainwright maintains a Buy rating and $20 price target; the broader analyst consensus is “Moderate Buy,” with an average target of $13.80.
• Iovance’s latest quarter showed improving commercial performance: revenue rose 64.8% year over year to $121.47 million, beating expectations, while its $0.05-per-share loss was narrower than forecast. Management reaffirmed its 2026 revenue outlook.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Stock analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for Iovance Biotherapeutics in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($0.40) for the year, up from their previous estimate of ($0.49). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics' current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics' Q4 2026 earnings at ($0.05) EPS and FY2027 earnings at ($0.13) EPS.

A number of other analysts have also weighed in on the stock. Mizuho upped their target price on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 18th. Citigroup reiterated an "outperform" rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Zacks Research raised shares of Iovance Biotherapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a report on Tuesday, September 29th. Finally, TD Cowen lifted their price objective on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Iovance Biotherapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $13.80.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $8.04 on Monday. The business's 50-day moving average is $11.37 and its two-hundred day moving average is $5.97. The firm has a market capitalization of $3.64 billion, a P/E ratio of -15.17 and a beta of 0.88. Iovance Biotherapeutics has a 1 year low of $2.08 and a 1 year high of $15.37.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. Iovance Biotherapeutics had a negative return on equity of 29.71% and a negative net margin of 58.20%. The firm had revenue of $121.47 million during the quarter, compared to analysts' expectations of $115.98 million. Iovance Biotherapeutics's revenue was up 64.8% compared to the same quarter last year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in IOVA. BlackRock Inc. acquired a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth $153,744,000. Palo Alto Investors LP purchased a new stake in Iovance Biotherapeutics during the second quarter worth about $22,032,229. Bank of America Corp DE purchased a new stake in Iovance Biotherapeutics during the second quarter worth about $20,773,000. Knott David M Jr acquired a new position in Iovance Biotherapeutics during the first quarter worth about $5,616,000. Finally, Rice Hall James & Associates LLC acquired a new position in Iovance Biotherapeutics during the second quarter worth about $6,406,000. Institutional investors and hedge funds own 77.03% of the company's stock.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

About Iovance Biotherapeutics

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, which are expanded in a laboratory and returned to the patient.

The company's lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.